EZH2 and nasopharyngeal carcinoma: Corresponding to methylome data, expression of EZH2 and other PRC2 members increased in NPC and many other types of cancers, including breast, prostate, kidney, lung, bladder, and liver cancers 41–44, and are promising therapeutic targets in cancer therapy.